At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
In Brief
A Phase 2 clinical trial evaluating Computed Tomography, Magnetic Resonance Imaging, and 1 other intervention for Recurrent Endometrial Endometrioid Adenocarcinoma and 4 related conditions. Active but no longer recruiting, targeting 62 participants across 582 sites.
Signals
Detailed Summary
This phase II trial studies how well tazemetostat works in treating patients with ovarian or endometrial cancer that has come back (recurrent). Chemotherapy drugs, such as tazemetostat, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Study Details
Timeline
Arms & Interventions
Patients receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scans and MRI on study.
Interventions
Undergo CT scan
Undergo MRI
Given PO